Stay updated on Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page
- Check6 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4, indicating a newer release version. This appears to be a metadata update rather than a change to the study details.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page’s displayed system revision updated from v3.5.2 to v3.5.3, indicating a minor platform/version change without changing the study details.SummaryDifference0.0%

- Check34 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No user-facing content changes are indicated.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision: v3.5.0 was added and v3.4.3 was removed on the page. This appears to be an administrative version update that does not modify the study details.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page. No substantive changes to study content or eligibility criteria are indicated.SummaryDifference0.0%

- Check98 days agoChange DetectedAdded Revision: v3.4.2 and removed a government funding lapse notice alongside the prior Revision: v3.4.1; these are site maintenance/version updates and do not affect study content, eligibility criteria, or results pages. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.